Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰 关于使用部分暂时闲置募集资金及部分自有资金进行现金管理的公告 | 2025-03-21 | Chinese | |
| 百奥泰 第二届监事会第十八次会议决议的公告 | 2025-03-21 | Chinese | |
| 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分暂时闲置募集资金及部分自有资金进行现金管理的核查意见 | 2025-03-21 | Chinese | |
| 百奥泰 关于戈利木单抗注射液（BAT2506）上市许可申请获得受理的公告 | 2025-03-13 | Chinese | |
| 百奥泰 关于独立董事任期满六年辞职的公告 | 2025-03-05 | Chinese | |
| 百奥泰 关于董事、高级管理人员辞职的公告 | 2025-03-05 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 39229672 | 百奥泰 关于使用部分暂时闲置募集资金及部分自有资金进行现金管理的公告 | 2025-03-21 | Chinese | ||
| 39229663 | 百奥泰 第二届监事会第十八次会议决议的公告 | 2025-03-21 | Chinese | ||
| 39229656 | 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分暂时闲置募集资金及部分自有资金进行现金管理的核查意见 | 2025-03-21 | Chinese | ||
| 39229650 | 百奥泰 关于戈利木单抗注射液（BAT2506）上市许可申请获得受理的公告 | 2025-03-13 | Chinese | ||
| 39229644 | 百奥泰 关于独立董事任期满六年辞职的公告 | 2025-03-05 | Chinese | ||
| 39229634 | 百奥泰 关于董事、高级管理人员辞职的公告 | 2025-03-05 | Chinese | ||
| 39229627 | 百奥泰 关于自愿披露公司通过高新技术企业重新认定的公告 | 2025-02-27 | Chinese | ||
| 39229617 | 百奥泰 2025年第一次临时股东大会法律意见书 | 2025-02-26 | Chinese | ||
| 39229604 | 百奥泰 2025年第一次临时股东大会决议公告 | 2025-02-26 | Chinese | ||
| 39229591 | 百奥泰 2024年度业绩快报公告 | 2025-02-25 | Chinese | ||
| 39229582 | 百奥泰 2025年第一次临时股东大会会议资料 | 2025-02-13 | Chinese | ||
| 39229572 | 百奥泰 关于与Intas Pharmaceuticals Ltd.就BAT2506（戈利木单抗）注射液签署授权许可与商业化协议的公告 | 2025-02-10 | Chinese | ||
| 39229561 | 百奥泰 自愿披露关于注射用BAT1006联合曲妥珠单抗及化疗治疗乳腺癌获得药物临床试验批准通知书的公告 | 2025-02-10 | Chinese | ||
| 39229553 | 百奥泰 关于召开2025年第一次临时股东大会的通知 | 2025-02-10 | Chinese | ||
| 39229543 | 百奥泰 关于司库奇尤单抗注射液（BAT2306）上市许可申请获得受理的公告 | 2025-02-07 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.